In a two-part op-ed, Dr. Henry Miller of the Hoover Institute looks at FDA and asks two critical questions:
Can the Agency undo the paralyzing effects of decades of risk averse regulation?
What impact could the new bills now being discussed in Congress have?
The article's thought provoking, whatever your political leanings. Stay tuned to March's issue of
Pharmaceutical Manufacturing, for a cover story on FDA.
